- Interim analysis showed positive preliminary results for maintaining patients without mechanical ventilation and reducing the mortality rate, with shortened time to recovery and hospitalization duration
- A reduction in key pro-inflammatory cytokines and chemokines critically involved in cytokine release syndrome (CRS) was observed in patients treated with plonmarlimab compared to placebo
- Plonmarlimab treatment was well tolerated with no significant safety concerns in patients with severe COVID-19
- I-Mab plans to continue advancing the study in the U.S. and begins to explore other CRS-related opportunities
https://finance.yahoo.com/news/mab-reports-positive-interim-analysis-120000996.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.